CClinicalTrials.gg
Not yet recruitingNCT06841900Updated Feb 28, 2025

Implementation of the International Classification of Functioning, Disability and Health Model in Paediatric Cochlear Implant Recipients

An observational study in Cochlear Impant Children, sponsored by University Hospital, Antwerp. Not yet recruiting at 6 sites in 6 countries. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by University Hospital, Antwerp · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Sex
All
01

Study summary

The aim of this study is to implement the International Classification of Functioning, disability and health (ICF) in paediatric Cochlear Implant (CI) recipients (\<18 years) with prelingual sensorineural hearing loss in a multicenter prospective study to evaluate audiological rehabilitation after cochlear implantation. For this, ICF qualifiers which denote the magnitude of the level of health or severity of the problem will be quantified. Outcome measures include four questionnaires and three standard audiological examinations. Subjects will be assessed up to 1 month before implantation and 3 months, 6 months and 1 year post the activation of the speech processor.

02

Conditions studied

  • Cochlear Impant Children
03

In context

Lead sponsor

University Hospital, Antwerp is the lead sponsor of 234 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Paediatric Cochlear Implant (CI) recipients (\<18 years) with prelingual sensorineural hearing loss

Inclusion criteria

General

  • Children aged \< 18 years with prelingual bilateral severe-to-profound HL
  • Signed and dated informed consent, informed permission and/or minor's assent.
  • Willingness to participate in evaluations, test sessions, and medical follow-up sessions as defined in the protocol.
  • Physical and mental competence to participate in fitting of the device and follow-up sessions as defined in the protocol.

Audiological

  • Completion of hearing assessment battery showing suitability of the CI candidates.
  • Compliance with cochlear implant candidate selection criteria of the implanting centre.
  • First cochlear implantation Medical
  • Patent cochlea, as evidenced by High-resolution computed tomography (HRCT) and/or Magnetic Resonance Imaging (MRI).

Exclusion criteria

Exclusion Criteria:

General

  • Re-implantation of the cochlear implant
  • No motivation to participate in the study and/or unreasonable expectations. Medical
  • Presence of contra-indications for surgery in general and cochlear implantation in particular.
  • Presence of central auditory lesions.
  • Any disorder that may relate to an increased risk of skin flap problems Use of one of the following electrodes for implantation
  • Compressed
  • Split
  • Any type of custom made electrodes
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Cochlear Implant (CI) recipients (<18 years) with prelingual sensorineural hearing loss

    Cochlear Implant (CI) recipients (\<18 years) with prelingual sensorineural hearing loss

    Device: Cochlear Implantation

Interventions

  • DeviceCochlear Implantation

    Standard cochlear implantation

06

What researchers measure

Primary outcomes

  1. Change in LittlEARS® Auditory Questionnaire (LEAQ)

    The LittlEARS® Auditory Questionnaire (LEAQ) was created to aid professionals and caregivers in the assessment of auditory capabilities among infants and toddlers experiencing hearing impairment. Grounded in the observations made by caregivers concerning the auditory responses exhibited by their children in everyday settings, this questionnaire comprises 35 questions tailored to specific age groups, necessitating responses of either 'yes' or 'no'. These questions are designed to capture significant milestones in auditory development during the initial two years of life or within the first two years following the onset of hearing intervention for children utilizing hearing devices. The questionnaire is suitable for children up to 24 months old, or with a hearing age of 24 months.

    Time frame: 1 month before implantation and 3 months, 6 months and 1 year post the activation of the speech processor

  2. Change in Speech, Spatial and Qualities of Hearing Scale for Parents (SSQ-P)

    The original SSQ was adapted for use in children, resulting in the development of the SSQ-P. Each of the 23 items in the questionnaire presents a scenario followed by a question regarding the child's hearing ability within that scenario. These items are categorized into three dimensions: speech perception, spatial hearing, and qualities of hearing. Parents are tasked with providing a rating between 0 and 10 for each item, where 0 signifies that the child could not perform in the scenario at all and 10 indicates perfect performance. Additionally, parents are asked to indicate how frequently the scenario would occur and to rate the importance of the listening skills required for that scenario.

    Time frame: 1 month before implantation and 3 months, 6 months and 1 year post the activation of the speech processor

  3. Change in Speech Intelligibility Rating (SIR)

    The Speech Intelligibility Rating (SIR) comprises spoken passages, wherein the degree of intelligibility is evaluated using an interval scale spanning from 0 to 10, ensuring uniformity in rating perception. The SIR assessment uses 20 standardized passages delivered by a single speaker, each identified as possessing comparable levels of intelligibility. The SIR is typically used in children with hearing loss from around the age of 2 years old .

    Time frame: 1 month before implantation and 3 months, 6 months and 1 year post the activation of the speech processor

  4. Parent's Evaluation of Aural/Oral Performance of Children (PEACH)

    The PEACH is a 13-item questionnaire designed for parental assessment of a 3- to 7-year-old child's aural and oral abilities in everyday life. The PEACH asks parents to consider their child's listening behaviors over the past week and then assigns a numerical value to the answers ranging from 0 (Never or 0 %) to 4 (Always or 75 to 100 %). The PEACH questions assess listening behaviors in both quiet and noisy surroundings.

    Time frame: 1 month before implantation and 3 months, 6 months and 1 year post the activation of the speech processor

  5. Standard pure tone audiometry, Behavioral Observation Audiometry (BOA), Visual Reinforcement Audiometry (VRA) or Play Audiometry

    Standard pure tone audiometry, Behavioral Observation Audiometry (BOA), Visual Reinforcement Audiometry (VRA) or Play Audiometry will be performed according to current clinical standards (ISO 8253-1, 2010), depending on the age of the participant. Pre- and postoperatively, best-aided audiometry will be measured at 250, 500, 1000, 2000, 4000 and 8000 Hz using warble tones in sound field in a sound treated booth. The loudspeaker will be placed in front of the participant at ear level at 1 meter distance. The best-aided pure tone average (PTA4, primary outcome measurement) will be calculated by averaging participants' hearing thresholds at 500, 1000, 2000 and 4000 Hz in best-aided condition.

    Time frame: 1 month before implantation and 3 months, 6 months and 1 year post the activation of the speech processor

  6. Auditory Brainstem Response (ABR) Audiometry

    ABR audiometry involves the generation of an evoked potential through a brief auditory stimulus (e.g., click, chirp, etc.) transmitted via an acoustic transducer (insert earphone or headphone). The resulting waveform response is detected by surface electrodes positioned at the vertex of the scalp and ear lobes. The signal's amplitude is averaged and plotted against time and waveform peaks are identified as I-VII. These waveforms typically occur within a 10-millisecond window following a click stimulus presented at high intensities (70-90 dB normal hearing level \[nHL\]). ABR audiometry is suitable for children of all ages.

    Time frame: 1 month before implantation and 3 months, 6 months and 1 year post the activation of the speech processor

  7. Ling Sounds (detection/discrimination)

    For Ling sound detection, the participants' detection of six sounds (oo, ah, ee, mm, sh, ss) will be observed in a variety of game formats. In the clinic, each sound is presented six times without lipreading, and the child simply responds. Score "S" will be given if the skill is emerging, score "A" will be given if the child has been observed to carry out the tasks consistently. For Ling discrimination, the phoneme "ee" will be repeated and all six Ling Sounds will be randomly inserted. Score "S" will be given if the child is consistently able to discriminate any one sound out of the six, score "A" will be given if the child is consistently able to discriminate all six sounds. The Ling test is suitable for children from approximately 6 months of age to adulthood.

    Time frame: 1 month before implantation and 3 months, 6 months and 1 year post the activation of the speech processor

Secondary outcomes

  1. Subject Demographics

    Subject demographics will be retrieved from the participants' medical file or by asking the parents if the information is not available. The 11th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-11) classification will be used to code subjects' health conditions.

    Time frame: 1 month before implantation and 3 months, 6 months and 1 year post the activation of the speech processor

07

Study locations

6 sites
  • Fiona Stanley Fremantle Hospital Group
    Perth, Australia
    • Dayse Tavora-Viera · Contact · dayse.tavora@gmail.com · +61 8 6488 4880
    • Aanand Acharya · Contact
    • Dayse Tavora-Viera · Contact
  • University Hospital Antwerp
    Edegem, 2650, Belgium
  • University Clinic of Würzburg
    Würzburg, Germany
    • Anja Kurz · Contact · Kurz_A@ukw.de · +49 - 931 201 21701
    • Anja Kurz · Contact
    • Rudolf Hagen · Contact
  • World Hearing Centre
    Warsaw, Poland
    • Artur Lorens · Contact · a.lorens@ifps.org.pl · 954-404-6477
    • Artur Lorens · Contact
    • Piotr Skarzynski · Contact
    • Henryk Skarzynski · Contact
  • King Abdullah Ear Specialist Center (KAESC)
    Riyadh, Saudi Arabia
    • Medhat Yousef · Contact · myousef@ksu.edu.sa · +966 1 4670888
    • Medhat Yousef · Contact
    • Abdulrahman Hagr · Contact
  • Hospital La Paz
    Madrid, Spain
    • Miryam Calvino · Contact · miryamcf@yahoo.com · +34 917 27 70 00
    • Miryam Calvino · Contact
    • Luis Lasaletta · Contact
    • Javier Gavilan · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06841900
Lead sponsor
University Hospital, Antwerp
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Mar 2025 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Feb 28, 2025

Study contacts

Ellen Andries, PhD AUD
Contact
ellen.andries@uza.be
+32 3 275 7372
Griet Mertens, PhD AUD
Contact
griet.mertens@uza.be

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion